<DOC>
	<DOCNO>NCT00772005</DOCNO>
	<brief_summary>The primary objective study evaluate whether armodafinil treatment effective placebo adjunctive therapy antipsychotic medication alleviate negative symptom schizophrenia</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Armodafinil Adjunctive Therapy Adults With Schizophrenia</brief_title>
	<detailed_description>This study design powered evaluate efficacy safety armodafinil treatment dosages 150 , 200 , 250 mg/day compare placebo 24 week adjunctive therapy antipsychotic medication ( olanzapine , oral risperidone , paliperidone ) adult schizophrenia clinically stable study entry . Specifically , effect armodafinil treatment negative symptom schizophrenia primary assessment study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Key The patient diagnosis schizophrenia accord DSMIVTR criterion patient clinically stable nonacute phase illness . Documentation patient receive treatment olanzapine , oral risperidone , paliperidone schizophrenia least 6 week prior screen visit stable dose antipsychotic medication least 4 week prior screen visit . The patient good health ( except diagnosis schizophrenia ) judge investigator . Women childbearing potential ( surgically sterile 2 year postmenopausal ) must use medically accept method contraception must agree continue use method duration study 30 day participation study . Acceptable method contraception include barrier method spermicide , intrauterine device ( IUD ) , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method , document abstinence . The patient PANSS negative symptom score 15 screen baseline visit . Key The patient severity rating moderate bad item PANSS positive symptom subscale . The patient Axis I disorder accord DSMIVTR criterion , include schizoaffective disorder , apart schizophrenia nicotine dependence , Axis II disorder would interfere conduct study . The patient moderate severe depressive symptom , indicate CDSS . The patient current active suicidal ideation , imminent risk selfharm , history significant suicidal ideation suicide attempt time past cause concern present . The patient tardive dyskinesia , akathisia , moderate bad level extrapyramidal symptom , clinically significant movement disorder . The patient history cutaneous drug reaction drug hypersensitivity reaction , history clinically significant hypersensitivity reaction , history multiple clinically relevant allergy . The patient pregnant lactate woman . The patient previously receive modafinil armodafinil , patient know sensitivity ingredient study drug tablet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>